Abstract:Pinyi Zhang, 1 Jianlong Bu, 2 Xiaohong Wu, 1 Lin Deng, 1 Meng Chi, 1 Chao Ma, 3 Xiaoding Shi, 1 Guonian Wang 3 1 Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 2 Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 3 Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Harbin, People's Republic of China Correspondence: Guonian Wang Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin 150081, People's Republic of China Tel +86 15804616023 Email wangguonian609cn@aliyun.com Background: Sustained morphine treatment for cancer pain has been limited due to analgesic tolerance. Opioid receptor internalization and desensitization mediated by downregulation of mu-opioid receptor (MOR) expression have been confirmed as one of the mechanisms of chronic morphine tolerance. In addition to the opiate system, the α 2-adrenergic system is involved in the development of morphine tolerance. Several studies reported that co-administration of α 2-adrenoceptor agonist dexmedetomidine inhibits morphine tolerance in normal or neuropathic pain animals. However, the effect of dexmedetomidine on morphine tolerance has not been studied in cancer pain. Therefore, we investigated the effect of intrathecal injection of dexmedetomidine on the development of morphine tolerance in cancer pain and on the expression of MOR in the spinal cord of morphine-tolerant cancer pain rats. Methods: The model was established using a rat's right hind paw injection of Walker 256 cancer cells. Subcutaneous morphine (10mg/kg) was administrated twice daily for 7 days; meanwhile, the rats received intrathecal α 2-adrenoceptor agonist dexmedetomidine (10μ/kg) or antagonist MK-467 (0.25mg/kg) in test groups. Rats receiving drug vehicle served as the control group. Antinociception was detected by von Frey filaments and hot-plate tests. The expression of MOR in the spinal cord was examined through real-time reverse transcription polymerase chain reaction and Western blotting. The data were analyzed via analysis of variance followed by Student t -test with Bonferroni correction. Results: Seven-day chronic morphine administration elicited notable analgesic tolerance in the rats with cancer pain. Co-administration of α 2-adrenoceptor agonist dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance, which could be blocked by α 2-adrenoceptor antagonist MK-467. Furthermore, pre-treatment of dexmedetomidine significantly upregulated MOR protein expression without a notable change in MOR mRNA expression in the spinal cord. Conclusion: Our findings suggest that intrathecal injection of dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance in cancer pain, potentially by upregulating MOR expression in the spinal cord. The α 2-adrenoceptor agonist may provide a more versatile analgesia option for morphine treatment for cancer pain. Keywords: μ-opioid receptor, MOR, α 2-adrenoceptor, α 2-AR, dexmedetomidine, DEX, morphine tolerance, cancer pain

Disruption of Δ-Opioid Receptor Phosphorylation at Threonine 161 Attenuates Morphine Tolerance in Rats with CFA-induced Inflammatory Hypersensitivity

Disruption of Cdk5-Associated Phosphorylation of Residue Threonine-161 of the Delta-Opioid Receptor: Impaired Receptor Function and Attenuated Morphine Antinociceptive Tolerance

Inhibition of SNAP-25 Phosphorylation at Ser187 is Involved in Chronic Morphine-induced Down-regulation of SNARE Complex Formation

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

A54 DELTA OPIOID RECEPTOR SIGNALING MEDIATES OPIOID INDUCED TOLERANCE AND HYPERALGESIA IN COLONIC SENSORY NERVES

Separation of Acute Desensitization and Long-Term Tolerance of µ-Opioid Receptors Is Determined by the Degree of C-Terminal Phosphorylation

T394A Mutation at the μ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice

Upregulation of μ-Opioid Receptor in the Rat Spinal Cord Contributes to the α2-Adrenoceptor Agonist Dexmedetomidine-Induced Attenuation of Chronic Morphine Tolerance in Cancer Pain

Phosphorylation of Neurofilament Light Chain in the VLO Is Correlated with Morphine-Induced Behavioral Sensitization in Rats

Identification of G protein-coupled receptor kinase 2 phosphorylation sites responsible for agonist-stimulated δ-opioid receptor phosphorylation

Tiam1-mediated maladaptive plasticity underlying morphine tolerance and hyperalgesia

The absence of endogenous β-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation

Phosphorylation of TRPV1 by Cyclin-Dependent Kinase 5 Promotes TRPV1 Surface Localization, Leading to Inflammatory Thermal Hyperalgesia

Involvement of Protein Kinase C in Morphine Tolerance at Spinal Levels of Rats

Src Kinase Inhibition Attenuates Morphine Tolerance without Affecting Reinforcement or Psychomotor Stimulation

Early Single Aspirin-triggered Lipoxin Blocked Morphine Anti-Nociception Tolerance Through Inhibiting NALP1 Inflammasome: Involvement of PI3k/Akt Signaling Pathway

Role of P2X7 Receptor-Mediated IL-18/IL-18R Signaling in Morphine Tolerance: Multiple Glial-Neuronal Dialogues in the Rat Spinal Cord.

Delta opioid receptor activation modulates affective pain and modality‐specific pain hypersensitivity associated with chronic neuropathic pain

Microglial TLR4-induced TAK1 phosphorylation and NLRP3 activation mediates neuroinflammation and contributes to chronic morphine-induced antinociceptive tolerance

Inhibitory Effects of Mas-Related Gene C Receptor on Chronic Morphine-Induced Spinal Glial Activation in Rats

Chronic morphine treatment induces sex- and synapse-specific cellular tolerance on thalamo-cortical mu opioid receptor signaling